Loading...

STOK STOKE THERAPEUTICS INC Management Changes 8-K Filing

STK

STK

STOKE THERAPEUTICS INC

(STOK)

2026 8-K

Quarterly Results

Board Appointment

Accounting Firm Change

CEO Bonus Approved

Lease Expansion

Data Presentation Announcement

Financial Results Report

CEO Appointment

Voting Frequency Decision

Product Expansion

Product Expansion

Financial Statements

Management Changes

Licensing Agreement

FDA Breakthrough Designation

Q3 Earnings Report

Lawsuit Settlement

Earnings Reports

Departure of Officer

Annual Meeting of Stockholders

Financial Results Announcement

Appointment of CFO and Resi...

Public Offering

New Data Announcement

Financial Results Announcement

Regulation FD and Other Events

Lease Extension

Announcement of Clinical Da...

Earnings Reports

Special Meeting Approval

Appointment of Director

Earnings Reports

Product Updates

Annual Meeting of Stockholders

Financial Results Announcement

FDA Approval for Higher Sin...

Financial Results

Amended and Restated Bylaws...

Business Update

External Links:

On February 13, 2026, Stoke Therapeutics, Inc. announced a discretionary bonus of $697,125 for CEO Ian F. Smith, awarded based on achieving 150% of the company's corporate goals since his appointment.

AI Assistant

STOKE THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.